Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Metrics to compare | OBIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOBIOPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.4x | −5.4x | −0.6x | |
PEG Ratio | 1.39 | 0.23 | 0.00 | |
Price/Book | 4.3x | 4.0x | 2.6x | |
Price / LTM Sales | 74.4x | 3.1x | 3.2x | |
Upside (Analyst Target) | 196.9% | 25.0% | 45.4% | |
Fair Value Upside | Unlock | −1.0% | 7.7% | Unlock |